ReviewMolecular diversity2026
Progress and application of activity-based protein profiling for the discovery of natural product targets.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics-driven precision medicine.iMeta · 2026Review
- AI-Driven Plant-Derived Anti-Infectives: Integrating Traditional Wisdom into Precision Medicine Against AMR.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Identifying natural products (NPs) targets is of great significance for the study of drug function mechanisms and the discovery of new compounds acting on the targets. Chemical proteomics technologies provide new perspectives, among which activity-based Protein Profiling (ABPP) has attracted much attention as a research hotspot. In this paper, we systematically review the application of various chemical proteomics technologies in natural product target identification, in which the development of ABPP is elaborated in detail, including the traditional biotin-labeled probe technology, the application of bioorthogonal strategy and photoaffinity cross-linking reaction of ABPP (AfBPP) and their advantages and disadvantages. Meanwhile, We also illustrate the joint application of ABPP with other technologies to demonstrate the innovative value of technology integration. Finally, the application examples of ABPP were introduced by categorizing from two perspectives of natural product types and disease research directions, showing the important value and unique advantages of ABPP in NPs target research, such as precisely identifying targets and providing key information for new drug development. However, each chemical proteomics technology still faces various challenges, such as the optimization of ABPP probe design and the control of the effect on the physiological state of the cell, which need to be further improved and perfected in the future to accelerate the drug development.
Indexed as
Identifiers
40986277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.